Telehealth Company Drops Compounded Semaglutide Weight Loss Claims After Novo Nordisk Ad Challenge

The market for compounded versions of blockbuster weight loss drugs has drawn a wave of advertising, and a matching wave of challenges to that advertising. One of those disputes, brought by Novo Nordisk against a telehealth company over its compounded semaglutide marketing, reached a resolution on July 24, 2026, when the National Advertising Division said the company had permanently dropped the claims at issue.

What NAD announced

BBB National Programs' National Advertising Division (NAD) said on July 24, 2026 that Willow Health Services, Inc., a telehealth company that markets compounded semaglutide products, had permanently discontinued the advertising claims that Novo Nordisk had challenged. NAD said it would treat the discontinued claims, for compliance purposes, as though NAD had recommended they be discontinued.

The announcement closed a matter that Novo Nordisk, the maker of the FDA-approved semaglutide medicines Ozempic and Wegovy, had brought against Willow's marketing of a compounded, non-approved version of the same active ingredient.

The claims Novo Nordisk challenged

According to BBB National Programs, the inquiry focused on express and implied claims Willow made about the benefits, efficacy, and safety of its compounded semaglutide products. The challenged claims included statements that the products were:

• proven to support weight loss;
• comparable to FDA-approved semaglutide products; and
• able to deliver effective weight loss without diet or exercise.

Novo Nordisk argued those claims were unsupported. In its earlier review, NAD said that reliance on a prescribing clinician's judgment did not, by itself, substantiate advertising claims, noting that an expert's conclusory statement or action is of little value without evidence. The July 2026 outcome resolved the matter through Willow's voluntary discontinuance rather than a finding that any specific claim was false.

How the case started, and why it was reopened

NAD first decided the Willow matter on December 4, 2025, recommending that the company modify or discontinue several health claims for its compounded semaglutide tablets. When Willow did not provide the advertiser statement that NAD's process requires, indicating whether it would comply, NAD referred the case to the Federal Trade Commission, to relevant state attorneys general, and to the platforms where the advertising appeared.

Following discussions involving the FTC, Willow returned to the self-regulatory process. NAD reopened the matter, and Willow then permanently discontinued the challenged claims. A referral of this kind is a procedural step, not a government finding of wrongdoing, and no FTC enforcement determination against Willow was announced as part of this resolution.

What the National Advertising Division is, and is not

NAD is the advertising self-regulation arm of BBB National Programs, an independent, industry-funded body. It reviews challenges to national advertising claims and issues recommendations. Participation is voluntary, and NAD cannot fine companies or order them to stop advertising. Its leverage comes from the referral pathway: when an advertiser declines to participate or comply, NAD can send the matter to the FTC and state regulators, who do have enforcement authority. NAD applies standards aligned with FTC advertising law, which requires that objective product claims be truthful and adequately substantiated.

Part of a broader push against compounded GLP-1 marketing

The Willow resolution is one piece of a larger effort by the branded drugmakers to police how compounded GLP-1 medicines are advertised. Across 2025 and 2026, Novo Nordisk and Eli Lilly, the maker of tirzepatide medicines Mounjaro and Zepbound, have brought multiple NAD challenges against compounding pharmacies, telehealth companies, and medspas that market compounded semaglutide and tirzepatide. Federal regulators have moved in parallel: the FDA has issued a rising share of warning letters over compounded drug advertising and has repeatedly stated that compounded drugs are not reviewed by the agency for safety and effectiveness the way approved drugs are, and are not equivalent to them.

Compounded semaglutide is prepared by compounding pharmacies rather than manufactured and approved as a finished drug product. The FDA does not review compounded preparations for safety, effectiveness, or quality before they are sold, which is a central reason branded manufacturers and regulators scrutinize comparative and efficacy claims made for them.

What this means for telehealth patients

For consumers weighing an online weight loss program, the case is a reminder that marketing language and clinical evidence are not the same thing. A claim that a compounded product is comparable to an FDA-approved medicine, or that it works without diet or exercise, is exactly the kind of assertion that advertising reviewers and regulators are now testing. The resolution does not decide whether any particular compounded product works or is safe for a given person. That is a clinical question, not an advertising one.

Practical notes and limits

This is general information, not medical or legal advice. If you are considering a compounded GLP-1 medication through a telehealth provider, a licensed clinician who evaluates you is the right source for whether it is appropriate, and the primary sources below are the record of what NAD actually decided. A few points worth keeping in mind:

• Compounded semaglutide is not an FDA-approved product, and the FDA has said compounded drugs are not reviewed for safety and effectiveness before marketing.
• Advertising claims that a compounded product matches or beats an approved drug are the type of comparative claim regulators and self-regulatory bodies scrutinize most closely.
• A NAD recommendation or referral is not a court judgment; it does not by itself establish that a company broke the law.
• Ask a licensed clinician about benefits, risks, and sourcing before starting any prescription weight loss treatment.